after stratification for disease-free interval and dominant sites of disease , patients were randomized to either cmf ( cyclophosphamide [ cyc ] , 100 mg/m2 orally , days 1 through 14 ; methotrexate [ mtx ] , 40 mg intravenously [ iv ] , days 1 and 8 ; 5-fluorouracil [ 5-fu ] , 500 mg/m2 iv , days 1 and 8 ) , or caf ( cyc , 100 mg/m2 orally , days 1 through 14 ; doxorubicin [ dox ] , 25 mg/m2 iv , days 1 and 8 ; 5-fu , 500 mg/m2 iv , days 1 and 8 ) , or cafvp ( caf as above plus vincristine [ vcr ] , 1.0 mg/m2 iv , days 1 and 8 ; and prednisone [ pred ] , 40 mg/m2 orally , days 1 through 14 ) .
C0013089
doxorubicin
C0054438
cafvp